UW-Madison Pioneers Ketamine Study for Teens with PTSD
UW-Madison Researchers Explore Ketamine for Adolescent PTSD Treatment
In an innovative approach to mental health treatment, researchers at the University of Wisconsin-Madison are set to begin a pioneering study examining the use of ketamine, a hallucinogenic drug, in conjunction with psychotherapy to treat adolescents suffering from post-traumatic stress disorder (PTSD). This study is believed to be the first of its kind to specifically target teens with PTSD, offering a new avenue for those who struggle with traditional psychotherapy.
The Study's Approach
Dr. Ryan Herringa, a child psychiatrist at UW Health and a leader of the study, highlights the challenges faced by many teens with PTSD, particularly those whose conditions stem from physical or sexual abuse or witnessing violence. Traditional psychotherapy, the current standard of care, often falls short for these individuals, as they may find it difficult to discuss their trauma. The introduction of ketamine, known for its mind-altering effects, aims to facilitate a more open and effective therapeutic dialogue.
"Our hope is that by combining ketamine with psychotherapy and doing it in a very safe and structured setting, we'll be able to enhance the therapeutic process of processing trauma memories for these kids," Herringa explained.
Study Details
The study is expected to commence early this year, enrolling five participants aged 15 to 17 with PTSD. Participants will receive three 90-minute intravenous infusions of ketamine over six weeks at UW Health’s American Family Children’s Hospital, with two therapists present to provide counseling. This early-stage trial will primarily assess the safety of administering ketamine to teens and explore its impact on PTSD symptoms.
Broader Implications
This research is part of a growing interest in the use of psychoactive substances for treating mental health disorders. UW-Madison has been at the forefront of this movement, with other studies investigating the use of psilocybin, the active compound in "magic mushrooms," for opioid and methamphetamine use disorders. Despite some promising results, such as a "substantial drop" in meth use among initial participants, the psilocybin study for meth addiction has been paused due to funding issues.
Looking Ahead
If successful, the ketamine study could pave the way for further research into the use of psychedelic drugs for treating PTSD and other mental health conditions in youth. This study represents a significant step forward in understanding and addressing the complex needs of adolescents with PTSD, offering hope for more effective treatments in the future.